Passage Bio, Inc.
PASG · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.02 | 0.02 | -0.03 |
| FCF Yield | -24.94% | -63.16% | -24.04% | -17.27% |
| EV / EBITDA | 0.73 | 1.20 | -1.70 | -2.43 |
| Quality | ||||
| ROIC | -16.41% | -22.92% | -16.45% | -21.01% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.63 | 0.67 | 0.90 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 54.29% | -63.71% | -13.27% | 43.16% |
| Safety | ||||
| Net Debt / EBITDA | 3.18 | 2.81 | 0.89 | 0.43 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,077.75 | -652.84 | -92.88 | -167.51 |